Horizon Discovery forms alliance with Caliper Life Science


Horizon Discovery have formed a partnership with Caliper Life Sciences, Inc. (NASDAQ: CALP) that expands Caliper Discovery Alliances and Services’ (CDAS) oncology cell line and screening capabilities for testing single drugs and combination therapies.


Hopkinton, Mass., April 9, 2008 -- Caliper Life Sciences, Inc. (NASDAQ: CALP) today
announced a partnership with Horizon Discovery Ltd. (Cambridge, UK) that expands Caliper
Discovery Alliances and Services’ (CDAS) oncology cell line and screening capabilities for
testing single drugs and combination therapies. Through this alliance, CDAS now offers
unique, genetically-defined, and isogenic human cancer cell lines that allow researchers to
better identify and characterize personalized drugs targeted at a specific subset of patients.

Isogenic cell-line pairs, where one cell line contains a genetic alteration or mutation of
interest and the other contains the normal gene, represent cell-based models that accurately
portray specific human diseases in the context of their matched normal genetic backgrounds.
The inclusion of isogenic cell-line pairs in the discovery process enables scientists to better
understand the mechanism of action of lead compounds, directly identify patient-relevant
compounds from large compound libraries, re-profile existing drugs for new therapeutic
indications, assess the efficacy of drug combinations, and identify potential side effects
earlier in the discovery process.

“The alliance with Horizon Discovery adds significant value to existing CDAS offerings and
illustrates Caliper’s commitment to providing accurate in vitro and in vivo models for
oncology research,” said David Manyak, Executive Vice President of Drug Discovery
Services, Caliper Life Sciences. “The addition of Horizon’s isogenic cell lines to our existing
oncology cell proliferation panel, and the ability to correlate results from these isogenic cell
lines to efficacy in specific patient populations, further solidifies Caliper’s in vitro-in vivohuman
(IIH) bridge. Access to these tools will enable researchers to enhance the success rate
and reduce the cost of discovering targeted monotherapy or combination therapies that better
treat disease with fewer adverse events.”

Rather than being a single disease, researchers now understand that there are numerous forms
of cancer, many of which are associated with specific genetic alterations among cancer
patient subpopulations. The discovery of targeted or personalized medicines that treat
patients with a specific genetic makeup is a long and difficult process. Using more predictive
cellular models that better reflect the complexity of biological systems will accelerate and
rationalize many aspects of the discovery process – including target selection, lead-compound
generation and identification of the most responsive patients for clinical studies. The
availability of such models also enables molecular diagnostic findings to be incorporated into
existing drug discovery processes.

“Our extensive panel of isogenic human cancer cell-lines is a key, previously missing, tool in
understanding the link between drug behavior and patients’ genetic mutations. Our
partnership with Caliper allows us to greatly expand the reach of our cell lines to assist
researchers that are focused on uncovering cancer therapies,” said Chris Torrance, CEO,
Horizon Discovery. “Together we aim to significantly accelerate the search for new and more
effective targeted or personalized drugs.”

About Horizon Discovery

Horizon Discovery is a translational genomics company founded in June 2007 and is
headquartered at the Babraham Research Campus, Cambridge, UK and with additional
research laboratories in Torino, Italy. Horizon’s goal is to convert new information on the
genetic causes of cancer into laboratory models that will facilitate the discovery of drugs that
target these defects. Central to this aim is Horizon Discovery’s offering of isogenic cell-lines,
which represent accurate models of defined cancer patient populations and their matched
normal genetic backgrounds – a missing link in the rational and efficient development of
novel targeted anti-cancer agents.

For more information, please visit http://www.horizondiscovery.com.

About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers
in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests
more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the
gap between in vitro assays and in vivo results and then translating those results into cures for
human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab
automation & liquid handling, optical imaging technologies, and discovery & development
outsourcing solutions.

For more information please visit http://www.caliperLS.com.

Caliper is a registered trademark of Caliper Life Sciences, Inc.

Investor Contact:
Peter F. McAree
Caliper Life Sciences

Media Contact:
Stacey Holifield/Michele Clement
Schwartz Communications


Horizon Discovery Group plc, a UK headquartered global life science company, is a world leader in gene editing and gene modulation.

Horizon Discovery